Niowave Plans $85M Lansing Isotope Plant, 73 Jobs by 2028
Lansing – October 16, 2026 -- Niowave is building an 80,000-square-foot medical radioisotope production facility in Lansing, Michigan, with a capital investment of more than $85 million and operations expected to start in 2028.
Labor Secretary Keith Sonderling toured Niowave's existing dedicated production facility and the construction site of its second plant. He also held a roundtable with company leaders on the production of medical radioisotopes for cancer treatments.
New plant to house up to six linear particle accelerators
The facility will contain up to six new linear particle accelerators and expand Niowave's capacity to produce Actinium-225, an isotope used in targeted alpha therapies for cancer. It will also include production space, radiochemistry laboratories, warehousing and administrative offices.